Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

429
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
429
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

354
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
354
Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

385
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
385

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TIME-trend and forecasting of the economic impact of inflammatory bowel disease in Catalonia: a population-based analysis.

Journal of medical economics·2026
Same author

Prevalence, incidence and mortality of pediatric inflammatory bowel disease in Catalonia (EPIBDCat).

Revista espanola de enfermedades digestivas·2026
Same author

Development and validation of the inflammatory bowel disease objective disability index (IBDODI).

Revista espanola de enfermedades digestivas·2026
Same author

Microbial signatures in psoriatic arthritis distinguish disease phenotypes and newly diagnosed inflammatory bowel disease independent of faecal calprotectin.

Annals of the rheumatic diseases·2026
Same author

Hidradenitis suppurativa in patients with inflammatory bowel disease: a national multicenter study from the GETECCU-ENEIDA Registry.

Therapeutic advances in gastroenterology·2026
Same author

Multidisciplinary spondyloarthrtis and inflammatory bowel disease unit: Report of 7 years' experience.

Reumatologia clinica·2026

Related Experiment Video

Updated: Apr 26, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K

How to compare biologic drugs.

Xavier Calvet1, Juan Vicente Esplugues2,

  • 1Servicio de Aparato Digestivo, Corporació Sanitària Universitària Parc Taulí, Universitat Autònoma de Barcelona, Sabadell, España; CIBERehd, Madrid, España.

Reumatologia Clinica
|July 22, 2014
PubMed
Summary

Evaluating biological drugs requires improved evidence. Current comparisons are unreliable, necessitating direct, randomized non-inferiority trials against established treatments, not placebo, for better regulatory guidance.

Keywords:
Biologic drugsComparaciones indirectasEstudios de no inferioridadFármacos biológicosIndirect comparisonsNon inferiority studies

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

21.0K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

11.8K

Related Experiment Videos

Last Updated: Apr 26, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

21.0K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

11.8K

Area of Science:

  • Pharmacology
  • Clinical Trials
  • Regulatory Science

Background:

  • Current evidence for biological drug comparisons relies heavily on indirect comparisons.
  • These indirect comparisons exhibit significant methodological limitations and are generally unreliable for robust evaluation.

Framework:

  • The consensus advocates for amending regulatory directives to prioritize direct, face-to-face randomized non-inferiority studies.
  • These studies should compare new biological treatments directly against current standards of care.

Implementation:

  • Avoidance of placebo-controlled trials is recommended in favor of comparative effectiveness studies.
  • Establishing consensus among regulatory agencies, scientific societies, industry, and health authorities is crucial.

Implications:

  • Defining clinically relevant differences for various conditions is essential for study design and interpretation.
  • This shift aims to enhance the reliability and clinical utility of evidence supporting biological drug evaluations.